People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| MorphImmune Inc. | — | Other Health Care | Series B | $32.1M | $139.7M | 2022 |
| Courage Therapeutics, Inc. | — | Biotechnology | Series A | $4.5M | $15.9M | 2025 |
Isaac Barchas at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Isaac Barchas on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ronald Martell | 1 | 4 |
| Roger Cone | 1 | 1 |
| Bruce Leutcher | 1 | 1 |
| Daniel Housman | 1 | 1 |
| Sunil Singhal, M.D. | 1 | 1 |
| Philip Low, Ph.D. | 1 | 1 |
| Clay B. Siegall, Ph.D. | 1 | 1 |
| Franklyn Prendergast, M.D., Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.